Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 31 to 40 of 1533

TitleReference numberPublishedLast updated
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Burosumab for treating X-linked hypophosphataemia in adultsTA993
Abaloparatide for treating osteoporosis after menopauseTA991
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackDG59
AnaphylaxisQS119
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTA988
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia BTA989
Tenecteplase for treating acute ischaemic strokeTA990
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986

Results per page

  1. 10
  2. 25
  3. 50
  4. All